MA50991B1 - Composition topique ophtalmique comprenent de l'acide dobesilique pour le traitement des maladies du segment postérieur de l' il - Google Patents

Composition topique ophtalmique comprenent de l'acide dobesilique pour le traitement des maladies du segment postérieur de l' il

Info

Publication number
MA50991B1
MA50991B1 MA50991A MA50991A MA50991B1 MA 50991 B1 MA50991 B1 MA 50991B1 MA 50991 A MA50991 A MA 50991A MA 50991 A MA50991 A MA 50991A MA 50991 B1 MA50991 B1 MA 50991B1
Authority
MA
Morocco
Prior art keywords
eye
treatment
acid
posterior segment
diseases
Prior art date
Application number
MA50991A
Other languages
English (en)
French (fr)
Other versions
MA50991A (fr
Inventor
Nortes Xavier Capdevila
Aquilué Javier Sanagustín
Gañán Maria Isabel Delgado
Original Assignee
Salvat Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salvat Lab Sa filed Critical Salvat Lab Sa
Publication of MA50991A publication Critical patent/MA50991A/fr
Publication of MA50991B1 publication Critical patent/MA50991B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA50991A 2017-12-04 2018-11-29 Composition topique ophtalmique comprenent de l'acide dobesilique pour le traitement des maladies du segment postérieur de l' il MA50991B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382832 2017-12-04
PCT/EP2018/082999 WO2019110416A1 (en) 2017-12-04 2018-11-29 Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye

Publications (2)

Publication Number Publication Date
MA50991A MA50991A (fr) 2020-10-14
MA50991B1 true MA50991B1 (fr) 2023-03-31

Family

ID=60673756

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50991A MA50991B1 (fr) 2017-12-04 2018-11-29 Composition topique ophtalmique comprenent de l'acide dobesilique pour le traitement des maladies du segment postérieur de l' il

Country Status (24)

Country Link
US (1) US20200390729A1 (enExample)
EP (1) EP3720428B1 (enExample)
JP (1) JP2021505554A (enExample)
KR (1) KR102756155B1 (enExample)
CN (1) CN111542316A (enExample)
AU (1) AU2018378981B2 (enExample)
BR (1) BR112020011160A2 (enExample)
CA (1) CA3083835A1 (enExample)
CL (1) CL2020001426A1 (enExample)
DK (1) DK3720428T3 (enExample)
ES (1) ES2941036T3 (enExample)
FI (1) FI3720428T3 (enExample)
HR (1) HRP20230319T1 (enExample)
HU (1) HUE061852T2 (enExample)
MA (1) MA50991B1 (enExample)
MX (1) MX2020005809A (enExample)
MY (1) MY205498A (enExample)
PH (1) PH12020550722A1 (enExample)
PL (1) PL3720428T3 (enExample)
PT (1) PT3720428T (enExample)
SG (1) SG11202004940VA (enExample)
SI (1) SI3720428T1 (enExample)
WO (1) WO2019110416A1 (enExample)
ZA (1) ZA202003944B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300017430A1 (it) * 2023-08-22 2025-02-22 Service Biotech srl Soluzione oftalmica in forma di collirio contenente una isoforma umana ricombinante di manganese superossido dismutasi (rmnsod) per la cura di patologie dell’occhio
CN117257963B (zh) * 2023-11-02 2024-07-16 广州准优生物科技有限公司 含脐带间充质干细胞外泌体的眼用药剂及其制备方法和用途
CN117643573B (zh) * 2024-01-29 2024-05-03 天津医科大学眼科医院 一种可递送药物至眼后节的纳米滴眼液及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE51421B1 (en) * 1980-08-01 1986-12-24 Smith & Nephew Ass Ophthalmic compositions containing triamterene
US9198886B2 (en) * 2006-08-16 2015-12-01 Pedro Cuevas Sánchez Use of 2,5-dihydroxybenzene for the treatment of ocular diseases
US20140309400A1 (en) * 2011-11-30 2014-10-16 Xigen Inflammation Ltd. Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Dry Eye Syndrome
PT2777699T (pt) * 2012-02-02 2017-07-07 Invesfovea S L Dietilamina-2,5-di-hidroxibenzenossulfonato para o tratamento de degeneração macular relacionada com a idade
US10947281B2 (en) * 2012-03-05 2021-03-16 Wayne State University Identification of channelrhodopsin-2 (ChR2) mutations and methods of use
US9884910B2 (en) * 2012-04-24 2018-02-06 Thrombogenics Nv Anti-PDGF-C antibodies
EP2875811A1 (en) * 2013-11-26 2015-05-27 Luis Antonio Outeirino Miguez Use of dobesilate for treating ocular haemorrhages

Also Published As

Publication number Publication date
AU2018378981A1 (en) 2020-07-16
PL3720428T3 (pl) 2023-05-08
KR102756155B1 (ko) 2025-01-20
ES2941036T3 (es) 2023-05-16
PT3720428T (pt) 2023-04-03
SG11202004940VA (en) 2020-06-29
WO2019110416A1 (en) 2019-06-13
PH12020550722A1 (en) 2021-02-15
HRP20230319T1 (hr) 2023-05-12
ZA202003944B (en) 2022-12-21
CA3083835A1 (en) 2019-06-13
JP2021505554A (ja) 2021-02-18
HUE061852T2 (hu) 2023-08-28
EP3720428B1 (en) 2023-01-11
CN111542316A (zh) 2020-08-14
KR20200096569A (ko) 2020-08-12
EP3720428A1 (en) 2020-10-14
US20200390729A1 (en) 2020-12-17
MX2020005809A (es) 2020-08-20
MA50991A (fr) 2020-10-14
DK3720428T3 (da) 2023-03-20
FI3720428T3 (fi) 2023-03-30
CL2020001426A1 (es) 2020-11-06
SI3720428T1 (sl) 2023-05-31
AU2018378981B2 (en) 2024-10-24
BR112020011160A2 (pt) 2020-11-17
MY205498A (en) 2024-10-23

Similar Documents

Publication Publication Date Title
EP4491229A3 (en) Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
MX2010003774A (es) Formulaciones oftalmicas acuosas.
JP2019524826A5 (enExample)
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
WO2017158366A3 (en) Ophthalmic delivery device and ophthalmic drug compositions
WO2007104541A3 (en) Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
Janowski et al. Concise review: using stem cells to prevent the progression of myopia—a concept
Lazreg et al. Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naïve patients and patients intolerant to other hypotensive medications
MA50991B1 (fr) Composition topique ophtalmique comprenent de l'acide dobesilique pour le traitement des maladies du segment postérieur de l' il
EP3416617B1 (en) Combination of an antiallergic agent with muscarinic antagonist and/or dopaminergic agonist for use in preventing/stopping of axial myopia in human
JP6267003B2 (ja) ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
EP3919052A4 (en) Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases
WO2013184650A3 (en) Treatment of ocular inflammatory diseases using laquinimod
HRP20211589T1 (hr) Uporaba proteoglikana 4 (prg4) za poboljšanje dinamičke vizuelne oštrine i aberacija višeg reda
Padhy et al. Bimatoprost (0.03%)-induced accommodative spasm and pseudomyopia
MA40847A (fr) Association comprenant de la spiruline et du palmitoyléthanolamide et/ou des sels ou des dérivés pharmaceutiquement acceptables de ceux-ci et leurs formulations, pour une utilisation dans la prévention et/ou le traitement d'états d'hyperactivité des tissus
RU2017111579A (ru) Способы лечения и предотвращения заболеваний глаз, расстройств и патологических состояний меланином и аналогами, предшественниками и производными меланина
EP4138841A4 (en) FORMULATION FOR THE TREATMENT OF EYE DISORDERS
Orman et al. Overview of pharmacological treatments for presbyopia
Jagadeesh et al. Visual performance with changes in eccentricity in PROSE device: A case report
MX2022006523A (es) Composicion que comprende budesonida para uso oftalmico.
JP6231783B2 (ja) 完全フロイントアジュバント投与による眼瞼状態の変化方法
EP4559529A3 (en) Isocyclosporin a for topical treatment of ocular diseases
Khandelwal Ocular snow storm: an unusual presentation of phacolytic glaucoma
IT202200008621A1 (it) Composizione farmaceutica in microemulsione per il trattamento dei disturbi del segmento anteriore dell'occhio